Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
AUTOR(ES)
Zufferey, Romain
FONTE
American Society for Microbiology
RESUMO
In vivo transduction of nondividing cells by human immunodeficiency virus type 1 (HIV-1)-based vectors results in transgene expression that is stable over several months. However, the use of HIV-1 vectors raises concerns about their safety. Here we describe a self-inactivating HIV-1 vector with a 400-nucleotide deletion in the 3′ long terminal repeat (LTR). The deletion, which includes the TATA box, abolished the LTR promoter activity but did not affect vector titers or transgene expression in vitro. The self-inactivating vector transduced neurons in vivo as efficiently as a vector with full-length LTRs. The inactivation design achieved in this work improves significantly the biosafety of HIV-derived vectors, as it reduces the likelihood that replication-competent retroviruses will originate in the vector producer and target cells, and hampers recombination with wild-type HIV in an infected host. Moreover, it improves the potential performance of the vector by removing LTR sequences previously associated with transcriptional interference and suppression in vivo and by allowing the construction of more-stringent tissue-specific or regulatable vectors.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=110499Documentos Relacionados
- Development of a Self-Inactivating Lentivirus Vector
- A conditional self-inactivating retrovirus vector that uses a tetracycline-responsive expression system.
- E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy.
- Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction
- Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors.